Verastem Congratulates Co-founder Robert Weinberg and Announces the Presentation of Data at the 2012 AACR Annual Meeting

Posted: Published on March 26th, 2012

This post was added by Dr. Richardson

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Verastem, Inc., (NASDAQ: VSTM - News) a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells (CSCs), congratulates Robert Weinberg, Ph.D., Verastem co-founder and co-chair of the Scientific Advisory Board, and announces the presentation of preclinical data at the American Association for Cancer Research annual meeting being held March 31 to April 4, 2012, in Chicago, IL.

Dr. Weinberg has been awarded the 2012 Pezcoller Foundation-AACR International Award for Cancer Research for his outstanding work in the fields of cancer genetics and cell biology. Dr. Weinberg will deliver an award lecture entitled Epithelial-Mesenchymal Transition, Cancer Stem Cells and Metastasis at the annual meeting on Monday, April 2, 2012.

Verastem will present data on its programs targeting the focal adhesion kinase (FAK; VS-4718 and VS-5095) and Wnt/Beta-catenin (VS-507) signaling pathways. Research on the FAK and Wnt/Beta-catenin signaling pathways has revealed critical roles for each in the survival and metastatic capability of CSCs. Verastem will present data on FAK and Wnt inhibition in preclinical cancer models as well as data on the development of biomarkers for companion diagnostic tests to identify CSCs.

The schedule for Dr. Weinbergs award address and Verastems poster presentations is as follows:

Dr. Weinbergs award lecture: Date & Time: Monday, April 2, 2012, at 5:30 p.m. (CT) Title: Epithelial-Mesenchymal Transition, Cancer Stem Cells and Metastasis Location: Skyline Ballroom of McCormick Place

Verastems poster presentations: Date & Time: Monday, April 2, 2012, from 1:00 to 5:00 p.m. (CT) Poster Title: The FAK Inhibitors VS-4718 and VS-5095 Attenuate Breast Cancer Stem Cell Function In Vitro and Tumor Growth In Vivo Abstract Number: LB-192 Location: McCormick Place West (Hall F), Poster Section 38

Date & Time: Monday, April 2, 2012, from 1:00 to 5:00 p.m. (CT) Poster Title: The Wnt Inhibitor VS-507 Reduces Cancer Stem Cell Function In Vitro and Tumorigenicity in Mice Abstract Number: LB-194 Location: McCormick Place West (Hall F), Poster Section 38

Date & Time: Monday, April 2, 2012, from 1:00 to 5:00 p.m. (CT) Poster Title: An Alternative Splicing Signature that Identifies Breast Cancer Stem Cells Abstract Number: LB-197 Location: McCormick Place West (Hall F), Poster Section 38

About Verastem, Inc.

Read more:
Verastem Congratulates Co-founder Robert Weinberg and Announces the Presentation of Data at the 2012 AACR Annual Meeting

Related Posts
This entry was posted in Mesenchymal Stem Cells. Bookmark the permalink.

Comments are closed.